Policy approaches intended to reshape biopharma research and development priorities need to focus on economic factors, not just regulatory pathways, FDA Center for Drug Evaluation and Research Director Patrizia Cavazzoni told a National Academy of Sciences, Engineering and Medicine panel developing a report on “Strategies to Better Align Investments in Innovations for Therapeutic Development with Disease Burden and Unmet Needs.”
IRA Impact On Biopharma R&D Bears Watching, US FDA’s Cavazzoni Says
The head of the US FDA’s drug center suggests that economic factors, including the Inflation Reduction Act, are potentially more important pathways shaping the focus of research and development than regulatory flexibility.
More from R&D
More from Pink Sheet
• By
EU-level joint clinical assessments conducted under the Health Technology Assessment Regulation need to be more flexible when it comes to evidence requirements, according to experts speaking at a gene and cell therapy conference.
• By
During its first quarter earnings call, Moderna avoided criticizing vaccine policy changes, but de-emphasized its flu/COVID-19 vaccine for those under age 50 and prioritized cancer programs.
• By
US HHS Advisor Calley Means said new pathways for root-cause treatments are part of the HHS Secretary Robert F. Kennedy Jr.’s vision for the FDA. But what most biopharma companies consider preventative medicines are not what he has in mind, nor does he seem to see those companies as part of the solution.